non small cell lung cancer treatments

Isiri-diki cell yemapapu cancer (NSCLC) imhando yakajairika yekenza yemapapu. Nzira dzekurapa dzeNSCLC dzakasiyana uye dzinoenderana nezvakati wandei, kusanganisira nhanho yegomarara, hutano hwemurwere hwese, uye genetic shanduko mukati mebundu. Gwaro iri rinopa mucherechedzo wenzira huru dzekurapa dzeNSCLC, kubva pakuvhiyiwa uye kurapwa nemwaranzi kusvika pakurapa kwakanangwa uye immunotherapy, kupa varwere nevachengeti ruzivo rwekuita sarudzo dzine ruzivo.Isiri-diki cell yemapapu cancer (NSCLC) iboka remakenza emapapu anoita nenzira yakafanana. Mhando huru dzeNSCLC dzinosanganisira adenocarcinoma, squamous cell carcinoma, uye hombe cell carcinoma. Kuongororwa kwakaringana, kusanganisa kutariswa uye kuyedzwa kwemamorekuru, kwakakosha pakuona nzira yekurapa inoshanda. Shandong Baofa Cancer Research Institute yakatsaurirwa kutsvagurudzo yegomarara uye kuvandudzwa kwemaitiro matsva ekurapa, dzidza zvakawanda pa https://baofahospital.com.Staging yeNSCLCNSCLC inoitwa pachishandiswa TNM system (Tumor, Node, Metastasis). Danho rinotsanangura saizi nenzvimbo yebundu rekutanga (T), ingave gomarara rapararira kumalymph nodes (N), uye kana gomarara racho raita metastasized kunzvimbo dziri kure (M). Matanho anotangira paI (danho rekutanga) kuenda kuIV (advanced stage) .Molecular Testing yeNSCLCMolecular test inoratidzira chaiyo gene mutations kana maprotein abnormalities mukati mebundu masero. Aya ma biomarker anogona kubatsira kuona kana murwere ari mumiriri weanonangwa marapirwo. Kuchinja kwakajairika kunosanganisira EGFR, ALK, ROS1, BRAF, nevamwe. Migumisiro yekuongororwa kwema molecular inonyanya kukanganisa zvisarudzo zvekurapa.Standard NSCLC KurapaKuvhiyaKuvhiya kunowanzo kuve kwekutanga-mutsara kurapwa kwekutanga-nhanho NSCLC (matanho I uye II). Chinangwa ndechekubvisa bundu uye chero malymph nodes ari pedyo. Mhando dzekuvhiya dzinosanganisira: Wedge Resection: Kubviswa kwechikamu chidiki chemapapu chakaita seweji. Segmentectomy: Kubviswa kwechikamu chikuru chemapapu pane kubviswa kwewedge. Lobectomy: Kubviswa kwerobe rose remapapu. Iyi ndiyo yakajairika nzira yekuvhiya yeNSCLC. Pneumonectomy: Kubviswa kwemapapu ose. Izvi hazvinyanyi kuitika uye zvakachengeterwa mamota akawandisa.Radiation TherapyRadiation therapy inoshandisa mwaranzi ine simba guru kuuraya maseru egomarara. Inogona kushandiswa seyokutanga kurapwa, mushure mekuvhiyiwa kuuraya chero asara maseru egomarara, kana kubvisa zviratidzo (palliative radiation). Mhando dzakasiyana dzeradiation therapy dzinosanganisira: Kunze Beam Radiation Therapy (EBRT): Radiation inoburitswa kubva pamushini uri kunze kwemuviri. Stereotactic Body Radiation Therapy (SBRT): Inoendesa madosi makuru emwaranzi kunzvimbo diki, yakanangwa chaizvo. Inowanzo shandiswa kwekutanga-nhanho NSCLC kana kuvhiya isiri sarudzo. Brachytherapy (Internal Radiation Therapy): Radioactive material inoiswa zvakananga mukati mebundu kana pedyo naro.ChemotherapyChemotherapy inoshandisa mishonga kuuraya masero egomarara mumuviri wose. Inowanzo shandiswa musanganiswa nekuvhiyiwa kana radiation therapy, kana sekutanga kurapwa kwepamberi NSCLC. Mishonga yakajairika yechemotherapy yeNSCLC inosanganisira cisplatin, carboplatin, paclitaxel, docetaxel, pemetrexed, uye gemcitabine.Targeted Therapy for NSCLC KurapaTargeted therapies mishonga inonangana nemamorekuru ane chekuita negomarara masero kukura uye kupona. Mishonga iyi inoshanda chete kana bundu riine genetic mutation kana protein abnormality.EGFR InhibitorsEGFR (epidermal growth factor receptor) inhibitors inoshandiswa kurapa. NSCLC ne EGFR mutations. Iyi mishonga inovhara EGFR protein, iyo inobatsira masero emukenza kukura. Mienzaniso inosanganisira: Gefitinib (Iressa) Erlotinib (Tarceva) Afatinib (Gilotrif) Osimertinib (Tagrisso)ALK InhibitorsALK (anaplastic lymphoma kinase) inhibitors anoshandiswa kurapa. NSCLC neALK gene rearrangements. Iyi mishonga inovhara ALK protein, iyo inobatsira masero emukenza kukura. Mienzaniso inosanganisira: Crizotinib (Xalkori) Ceritinib (Zykadia) Alectinib (Alecensa) Brigatinib (Alunbrig) Lorlatinib (Lorbrena)ROS1 InhibitorsROS1 inhibitors inoshandiswa kurapa NSCLC neROS1 gene rearrangements. Iyi mishonga inovhara puroteni yeROS1, iyo inobatsira masero egomarara kukura. Mienzaniso inosanganisira: Crizotinib (Xalkori) Entrectinib (Rozlytrek)BRAF InhibitorsBRAF inhibitors inoshandiswa kurapa. NSCLC ine BRAF V600E shanduko. Mishonga iyi inovhara protein yeBRAF. Mienzaniso inosanganisira: Dabrafenib (Tafinlar) Trametinib (Mekinist) (yakashandiswa pamwe chete neDabrafenib) Mamwe Mishonga YakanangwaMamwe marapirwo anonangwa anogona kushandiswa zvichienderana nekuchinja chaiko kuripo mubundu. Mienzaniso inosanganisira RET inhibitors (yeRET fusions) uye MET inhibitors (yeMET exon 14 skipping mutations) .Immunotherapy for NSCLC KurapaImmunotherapy mishonga inobatsira masoja emuviri kurwisa gomarara. Vanoshanda nekuvhara mapuroteni anodzivirira immune system kurwisa cancer maseru. Izvi zvinonyanya kushandiswa mukati NSCLC kurapwa.PD-1/PD-L1 InhibitorsPD-1 (programmed cell death protein 1) uye PD-L1 (programmed death-ligand 1) inhibitors inovhara PD-1/PD-L1 nzira, iyo inobatsira masero ekenza kunzvenga maitiro ezvirwere. Mienzaniso inosanganisira: Pembrolizumab (Keytruda) Nivolumab (Opdivo) Atezolizumab (Tecentriq) Durvalumab (Imfinzi) Cemiplimab (Libtayo)CTLA-4 InhibitorsCTLA-4 (cytotoxic T-lymphocyte-yakabatana neprotein 4) iyo CTLA-inodzivirira mapuroteni, CTLA-4 inodzivirira cancer maseru. Muenzaniso ndewe Ipilimumab (Yervoy), inowanzoshandiswa pamwe chete nePD-1 inhibitors.Kubatanidza TherapiesKazhinji, NSCLC mishonga zvinosanganisira kusanganiswa kwemishonga yakasiyana. Semuenzaniso, kuvhiyiwa kunogona kuteverwa nechemotherapy kana radiation therapy. Targeted therapy kana immunotherapy inogona kusanganiswa nechemotherapy. Iko kusanganiswa kwakananga kuchaenderana nemamiriro emurwere ega. Kuti uwane rumwe ruzivo nezve cancer research shanya Shandong Baofa Cancer Research Institute.Clinical TrialsClinical miedzo itsvakurudzo zvidzidzo zvinoongorora marapirwo matsva kana misanganiswa yemishonga. Varwere vane NSCLC inogona kufunga kutora chikamu muzviedzo zvekiriniki kuti uwane kurapa-kumucheto. Ruzivo rwezvekuedzwa kwekiriniki runogona kuwanikwa pawebhusaiti yeNational Cancer Institute uye mamwe masosi ane mukurumbira.Side Effect ManagementAll NSCLC mishonga zvinogona kukonzera maside effects. Zvakakosha kukurukura zvinogona kuitika nachiremba wako uye kudzidza maitiro ekuzvigadzirisa. Kutsigira kutsigirwa, kwakadai sekugadzirisa marwadzo uye rubatsiro rwekudya, kunogona kubatsira kuvandudza mararamiro panguva yekurapa.Prognosis uye Kutevera-Up CareThe prognosis for NSCLC zvinoenderana nedanho regomarara, hutano hwemurwere hwese, uye kuti gomarara rinoita sei pakurapwa. Kugara uchitevera kugadzwa kwakakosha kuti utarise kudzokorora uye kugadzirisa chero mhedzisiro yenguva refu yekurapwa.Disclaimer: Ichi chinyorwa chinopa ruzivo rwakakwana nezve isiri-diki cell cancer cancer (NSCLC) kurapwa uye hazvifanirwe kutorwa sezano rekurapa. Gara uchibvunza chiremba wako kana imwe nyanzvi yehutano inokwanisa kuti uwane mazano emunhu maererano nemamiriro ako ekurapa.